Résumé
The extensive molecular characterization of tumors with high throughput technologies has led to the segmentation of different tumors into very small molecularly defined subgroups. Many ongoing clinical trials are conducted only when specific molecular alterations are identified in tumor samples. In this review, we will describe the implementation of genome analysis in the clinical setting as it has expanded over the last four years in our Precision Medicine Program. This manuscript will also highlight the main limitations and challenges related to the development of broader and deeper genome analysis.
| langue originale | Anglais |
|---|---|
| Pages (de - à) | 99-106 |
| Nombre de pages | 8 |
| journal | Current Opinion in Genetics and Development |
| Volume | 24 |
| Numéro de publication | 1 |
| Les DOIs | |
| état | Publié - 1 févr. 2014 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Current Opinion in Genetics and Development, Vol 24, Numéro 1, 01.02.2014, p. 99-106.
Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs
TY - JOUR
T1 - Genomes in the clinic
T2 - The Gustave Roussy Cancer Center experience
AU - Lacroix, Ludovic
AU - Boichard, Amelie
AU - André, Fabrice
AU - Soria, Jean Charles
N1 - Funding Information: The GR comprehensive molecular screening program is being developed to complement our hospital's clinical trials strategy. The main molecular triage trials are shown in Table 1 . This whole initiative is supported by a variety of funding sources including: specific state grants, collaborative programs with biotech or pharmaceutical companies as well as philanthropic funding. The MSN ( M elanoma, S mall cell and N on-small cell lung cancer) trial was launched in 2009. It is a mono-centric molecular screening trial for tumor samples (either archived or newly collected) from patients with lung cancer and melanomas [ 8 ]. The SAFIR01 trial, which was launched in 2011 for patients with metastatic breast cancer and is now closed to recruitment, required dedicated frozen tumor biopsy samples. SAFIR01 was sponsored by UNICANCER, the former French Federation of Cancer Centers and funded by INCa [ 9 ]. The upcoming SAFIR02 trials will use NGS (70 genes), CGH and treatment arms according to molecular screening results for patients with metastatic breast and non-small cell lung cancer. MOSCATO (MOlecular Screening for Cancer Treatment Optimization), was launched in 2012. It is a mono-centric molecular triage trial for early phase I candidates and combines CGH array and sequencing of a gene panel performed on frozen tumor biopsy samples [ 10 ]. The WINTHER Trial was launched in 2013. It is an international non-randomized molecular triage study undertaken by the WIN consortium, requiring dedicated frozen tumor biopsy samples and normal matched tissue used to screen for mutations, translocations and copy number variations (CNV) by NGS, completed with RNA and microRNA exploration for tumors without actionable drug targets (R Kurzrock et al ., Communication, WIN Consortium, www.winconsortium.org ). Funding Information: The authors wish to thank the donors from the Revolution Cancer philanthropic initiative, Fondation Philantropia (Lombard Odier), Breast Cancer Research Foundation, Odyssea and Pération parrains Chercheurs, Programme Hospitalier de Recherche Clinique 2007 and 2010 and French National Cancer Institute (INCa). They also thank Lorna Saint Ange for editing.
PY - 2014/2/1
Y1 - 2014/2/1
N2 - The extensive molecular characterization of tumors with high throughput technologies has led to the segmentation of different tumors into very small molecularly defined subgroups. Many ongoing clinical trials are conducted only when specific molecular alterations are identified in tumor samples. In this review, we will describe the implementation of genome analysis in the clinical setting as it has expanded over the last four years in our Precision Medicine Program. This manuscript will also highlight the main limitations and challenges related to the development of broader and deeper genome analysis.
AB - The extensive molecular characterization of tumors with high throughput technologies has led to the segmentation of different tumors into very small molecularly defined subgroups. Many ongoing clinical trials are conducted only when specific molecular alterations are identified in tumor samples. In this review, we will describe the implementation of genome analysis in the clinical setting as it has expanded over the last four years in our Precision Medicine Program. This manuscript will also highlight the main limitations and challenges related to the development of broader and deeper genome analysis.
UR - http://www.scopus.com/inward/record.url?scp=84896713227&partnerID=8YFLogxK
U2 - 10.1016/j.gde.2013.11.013
DO - 10.1016/j.gde.2013.11.013
M3 - Review article
C2 - 24583392
AN - SCOPUS:84896713227
SN - 0959-437X
VL - 24
SP - 99
EP - 106
JO - Current Opinion in Genetics and Development
JF - Current Opinion in Genetics and Development
IS - 1
ER -